Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15232


Purpose:

The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma


Study summary:

Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.


Criteria:

Inclusion Criteria: - Conformed diagnosis of follicular lymphoma, grades 1,2 or 3 - No prior chemotherapy - No prior monoclonal antibody therapy - Bulky or symptomatic disease, stage II-IV - Performance status 0-2 Exclusion Criteria: - Impaired bone marrow reserve - Presence of CNS lymphoma - Serious nonmalignant disease or active infection


NCT ID:

NCT00177554


Primary Contact:

Principal Investigator
Samuel A Jacobs, MD
University of Pittsburgh


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.